Research, policy, and breakthroughs in women's health.
New research published this week links menopause hormone therapy to a lower risk of Alzheimer’s disease, while Canada has launched its first national investigator-led study to close critical gaps in menopause care. Additionally, recent findings highlight that a shorter reproductive lifespan may increase the risk of bronchiectasis.
A new large-scale study links higher blood levels of PFAS ("forever chemicals") in drinking water to menopause occurring approximately one year earlier. Concurrently, research indicates that women experiencing earlier menopause face accelerated cognitive decline and increased white matter brain injury. A survey also reveals that half of women report menopause negatively impacting their work attendance.
Recent coverage highlights the ongoing disconnect in US healthcare policy, where Medicare’s proposed 2027 fee schedule increases maternity payments but remains silent on menopause care. Meanwhile, new research emphasizes the critical need to prioritize women in longevity studies and better integrate reproductive health with cardiovascular disease prevention.
Women report that cognitive and emotional changes during perimenopause are more disruptive than physical symptoms, according to new survey data. Meanwhile, healthcare leaders warn that women's health remains an undermet need globally, with fragmented care systems failing to serve millions. A landmark review reveals menopause care is falling short worldwide despite increased public attention to the condition.
Women's health remains a focal point of national discourse this week, with major policy initiatives and investment trends showing significant momentum. The Lancet Commission released groundbreaking guidance on menstruation and lifespan approaches to female health, while social media platforms face renewed scrutiny for suppressing menopause-related advertising. Investment in women's health reached record levels last year, though researchers warn funding still lags far behind actual need.
A new surge in menopause awareness swept the cultural mainstream this week as Gen X punk icons rallied at Menopunkapalooza, while researchers project infertility cases will surge to 80 million globally by 2036, driven primarily by delayed motherhood among women over 35. Congressional efforts to protect reproductive access continue advancing.
A groundbreaking immunotherapy study offers hope for women with premature ovarian insufficiency, with 30% of participants achieving pregnancy. Meanwhile, regulatory updates loom for menopause management and contraceptive options, while employers expand women's health benefits nationwide.
Fresh research reveals hormone replacement therapy's unexpected bone health benefits for menopausal women, while a new toolkit addresses menopause care disparities in minority ethnic communities. The global women's health market continues rapid expansion, reaching $44.1 billion in 2025 with projected growth to $60.4 billion by 2034.
A landmark publication in The Lancet has officially recognized the broader metabolic impacts of PCOS by renaming it PMOS (Polyendocrine Metabolic Ovarian Syndrome). Meanwhile, Apple has expanded its Health app to track menopause and perimenopause symptoms, and new research from the University of Vermont highlights critical brain changes during menopause—reinforcing that this transition is a neurological milestone, not just a reproductive one.
New research links infertility to earlier menopause onset, while Melinda French Gates commits $215 million to women's reproductive and midlife health. Meanwhile, menopause research funding gaps persist despite affecting millions annually.
New research reveals estrogen loss during menopause triggers brain changes linked to memory decline, while a Mayo Clinic study finds hormone therapy use remains low despite proven benefits. Major women's health conferences and femtech innovation accelerate as investment in midlife health reaches critical mass.
This week brings critical updates on women's reproductive health misinformation, cognitive benefits of longer reproductive lifespans, and emerging menopause research. Healthcare leaders are addressing online myths about perimenopause and contraception, while new studies reveal how reproductive history impacts brain health in aging women.
This week brings a surge of breakthrough research on menopause, cognition, and cardiovascular health. A landmark study from Northwestern Medicine pinpoints estrogen loss in brain tissue as a driver of post-menopausal memory decline, while new data from the Nurses' Health Study links longer reproductive lifespans to better cognitive performance in older women. Meanwhile, Iowa State University launches a new study tracking how distinct menopause stages reshape brain health — and doctors and experts are pushing back against a wave of online perimenopause misinformation.
This week's top developments in women's health span a landmark market forecast for menopause therapies, a new award-winning probiotic designed specifically to support the pregnancy microbiome, and growing momentum around heart health gaps exposed at a major industry summit. Research and innovation are converging to address long-underserved life stages — from pregnancy to midlife and beyond.
A landmark study reveals that Polyendocrine Ovarian Syndrome (formerly PCOS) continues to affect women well beyond menopause, calling for lifelong care. Meanwhile, a new World Economic Forum radar—developed with the Gates Foundation—exposes a stark funding gap: women's health receives only 20% of R&D investment globally, with fewer than 3% of clinical trials being women-specific. Harvard's first Women's Health Student Summit and new American Academy of Sleep Medicine data on menopausal sleep disruption round out a week of urgent findings.
New American Heart Association data confirms that heart health measurably declines as women enter perimenopause, underscoring the transition as a critical window for cardiovascular intervention. On the investment front, Wellcome Leap and Pivotal have pledged $100 million to women's health research, bringing Leap's cumulative women's health investment to $250 million. Meanwhile, a new bicameral bill introduced this week aims to improve reproductive healthcare access for women with disabilities.
A major Cleveland Clinic report reveals a significant knowledge gap among women regarding their elevated Alzheimer's risk, while new research highlights breakthroughs for women over 50 including a landmark type 1 diabetes trial. Workplace menopause policy adoption remains critically low, with only 18% of women reporting their employer has one in place.
This week's top story is Oura's new platform update introducing a Menopause Impact Scale and deeper hormonal birth control tracking, marking a significant step in consumer femtech. A landmark study published in *New Scientist* finds that PCOS delays perimenopause onset in most patients, potentially extending fertility windows. Meanwhile, Mother's Day spotlights persistent equity gaps in women's health research, with advocates and academics calling for stronger investment in midlife and menopause science.
New research confirms that menopause-related symptoms are strongly correlated with sleep disruption, while a Georgia Tech study finds menopause remains the most under-researched life stage compared to other reproductive health topics. Meanwhile, Oura's smartring platform expands its women's health tracking capabilities with new birth control and menopause features, and a landmark Nature Aging study maps how female reproductive organs age at different rates.
This week's top developments in women's health span a major market projection placing the women's healthcare sector on a trajectory toward $600 billion by 2030, a significant policy debate over the UK's renewed Women's Health Strategy, and fresh nonhormonal therapy options reshaping menopause care. Meanwhile, new environmental research links air pollution and poor groundwater quality to disrupted reproductive timelines in women.
Create custom signals on any topic. AI curates and delivers 24/7.
Create SignalPowered by
